Indication BioScience
Indication.Bio is a clinical-stage drug discovery and development company dedicated to revolutionizing cardiovascular care. Their mission is to develop innovative therapies that improve health outcomes, treatment adherence, and quality of life. They focus on addressing unmet needs in cardiovascular health, such as statin intolerance, through science-driven approaches and advanced technologies. Their flagship program, Atorvo+, combines proven statin efficacy with advancements to reduce side effects, aiming to create safer and more effective cholesterol management therapies. They collaborate with industry leaders and leverage accelerated development pathways to bring transformative therapies to patients faster.
Industries
Nr. of Employees
medium (51-250)
Patents
Compositions and methods using a cannabinoid to enhance bioavailability of a statin
US-11786482-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-11234944-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-10835501-B2
View Details
Compositions and methods using a cannabinoid to enhance bioavailability of a statin
US-11786482-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-11234944-B2
View DetailsPharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US-10835501-B2
View DetailsProducts
Lead fixed‑dose combination statin therapy (lead development program)
A fixed‑dose combination therapy pairing a marketed statin with a complementary small molecule intended to reduce muscle-related side effects and improve adherence while maintaining lipid-lowering efficacy.
Lead fixed‑dose combination statin therapy (lead development program)
A fixed‑dose combination therapy pairing a marketed statin with a complementary small molecule intended to reduce muscle-related side effects and improve adherence while maintaining lipid-lowering efficacy.
Services
Outsourced execution and management of early‑phase clinical trials through partnered clinical research organizations.
Generation of preclinical safety and efficacy data to support candidate selection and clinical progression.
Strategic planning to leverage existing approvals and safety data to reduce regulatory timelines and program risk.
Outsourced execution and management of early‑phase clinical trials through partnered clinical research organizations.
Generation of preclinical safety and efficacy data to support candidate selection and clinical progression.
Strategic planning to leverage existing approvals and safety data to reduce regulatory timelines and program risk.
Expertise Areas
- Clinical trial management
- Pharmacokinetics and bioanalysis
- Fixed‑dose combination formulation development
- Preclinical safety and efficacy evaluation
Key Technologies
- Proteomics
- Pharmacokinetic studies
- Fixed‑dose combination formulation
- Bioanalytical assays